PPARA and fatty liver disease: In accordance, Hcy/AdoHcy has already been linked to elevated LDL-cholesterol [37], reduced apolipoprotein A-I expression [38], activation of adipocyte lipolysis leading to hepatic steatosis [39], increased VLDL secretion [36], as well as decreased PPARα/γ mRNA and protein levels [40].